Skip to main content

Table 1 Characteristics of the study cohort

From: A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

Characteristic

Dementia of the Alzheimer type

Dementia due to other reasons

p value

Number

23

17

 

Gender (male/female)

10/13

12/5

0.116*

Age (years)

69.0 ± 10.9

64.4 ± 11.0

0.199**

MMSE

22.6 ± 4.4

25.3 ± 2.4

0.041**

CDT (points)

3.0 ± 1.3

2.4 ± 1.2

0.147**

CSF Aβ1–40 (ng/ml)

11.87 ± 3.67 (n = 21)

10.08 ± 3.43 (n = 15)

0.147**

CSF Aβ1–42 (ng/ml)

0.59 ± 0.15 (n = 22)

1.20 ± 0.28 (n = 15)

< 0.0001**

CSF Aβ42/40 ratio

0.052 ± 0.18 (n = 21)

0.126 ± 0.30 (n = 15)

< 0.0001**

CSF tTau (pg/ml)

731.6 ± 283.6 (n = 22)

300.8 ± 116.5 (n = 15)

< 0.0001**

CSF pTau (pg/ml)

85.1 ± 32.0 (n = 22)

42.5 ± 12.2 (n = 15)

< 0.0001**

  1. Data presented as mean ± standard deviation, unless otherwise stated
  2. amyloid beta, CDT clock-drawing test, CSF cerebrospinal fluid, MMSE Mini-Mental State Examination, pTau phosphorylated Tau protein, tTau total Tau protein
  3. *Fisher’s exact test
  4. **Unpaired t test for differences between the two diagnostic categories